摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-phenethylamino)-5-chloro-6-methyl-1-(2-tert-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)pyrazinone | 199296-24-7

中文名称
——
中文别名
——
英文名称
3-(2-phenethylamino)-5-chloro-6-methyl-1-(2-tert-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)pyrazinone
英文别名
tert-butyl N-[5-[[[2-[3-chloro-2-methyl-6-oxo-5-(2-phenylethylamino)pyrazin-1-yl]acetyl]amino]methyl]-6-methylpyridin-2-yl]carbamate
3-(2-phenethylamino)-5-chloro-6-methyl-1-(2-tert-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)pyrazinone化学式
CAS
199296-24-7
化学式
C27H33ClN6O4
mdl
——
分子量
541.05
InChiKey
KUYKQJXMIAISPZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    38
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    125
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(2-phenethylamino)-5-chloro-6-methyl-1-(2-tert-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)pyrazinone盐酸 作用下, 以 乙酸乙酯 为溶剂, 以81%的产率得到N-(6-Amino-2-methyl-pyridin-3-ylmethyl)-2-(5-chloro-6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
    参考文献:
    名称:
    Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
    摘要:
    We have addressed the key deficiency of noncovalent pyridinone acetamide thrombin inhibitor L-374,087 (1), namely, its modest half-lives in animals, by making a chemically stable 3-alkylaminopyrazinone bioisostere for its 3-sulfonylaminopyridinone core. Compound 3 (L-375,378), the closest aminopyrazinone analogue of 1, has comparable selectivity and slightly decreased efficacy but significantly improved pharmacokinetics in rats, dogs, and monkeys to 1. We have developed an efficient and versatile synthesis of 3, and this compound has been chosen for further preclinical and clinical development.
    DOI:
    10.1021/jm980368v
  • 作为产物:
    参考文献:
    名称:
    Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
    摘要:
    We have addressed the key deficiency of noncovalent pyridinone acetamide thrombin inhibitor L-374,087 (1), namely, its modest half-lives in animals, by making a chemically stable 3-alkylaminopyrazinone bioisostere for its 3-sulfonylaminopyridinone core. Compound 3 (L-375,378), the closest aminopyrazinone analogue of 1, has comparable selectivity and slightly decreased efficacy but significantly improved pharmacokinetics in rats, dogs, and monkeys to 1. We have developed an efficient and versatile synthesis of 3, and this compound has been chosen for further preclinical and clinical development.
    DOI:
    10.1021/jm980368v
点击查看最新优质反应信息

文献信息

  • Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
    作者:Philip E. J. Sanderson、Terry A. Lyle、Kellie J. Cutrona、Dona L. Dyer、Bruce D. Dorsey、Colleen M. McDonough、Adel M. Naylor-Olsen、I-Wu Chen、Zhongguo Chen、Jacquelynn J. Cook、Carolyn M. Cooper、Stephen J. Gardell、Timothy R. Hare、Julie A. Krueger、S. Dale Lewis、Jiunn H. Lin、Bobby J. Lucas,、Elizabeth A. Lyle、Joseph J. Lynch,、Maria T. Stranieri、Kari Vastag、Youwei Yan、Jules A. Shafer、Joseph P. Vacca
    DOI:10.1021/jm980368v
    日期:1998.11.1
    We have addressed the key deficiency of noncovalent pyridinone acetamide thrombin inhibitor L-374,087 (1), namely, its modest half-lives in animals, by making a chemically stable 3-alkylaminopyrazinone bioisostere for its 3-sulfonylaminopyridinone core. Compound 3 (L-375,378), the closest aminopyrazinone analogue of 1, has comparable selectivity and slightly decreased efficacy but significantly improved pharmacokinetics in rats, dogs, and monkeys to 1. We have developed an efficient and versatile synthesis of 3, and this compound has been chosen for further preclinical and clinical development.
查看更多